These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27635950)

  • 1. Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma.
    Beck A; Eberherr C; Hagemann M; Cairo S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
    Cancer Biol Ther; 2016 Nov; 17(11):1168-1176. PubMed ID: 27635950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
    Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ginsenoside Rg1 impairs homologous recombination repair by targeting CtBP-interacting protein and sensitizes hepatoblastoma cells to DNA damage.
    Zhen N; Jin L; Ma J; Zhu J; Gu S; Wang J; Pan Q; Ni X; Xu M
    Anticancer Drugs; 2018 Sep; 29(8):756-766. PubMed ID: 29952772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights into diagnosis and therapeutic options for proliferative hepatoblastoma.
    Hooks KB; Audoux J; Fazli H; Lesjean S; Ernault T; Dugot-Senant N; Leste-Lasserre T; Hagedorn M; Rousseau B; Danet C; Branchereau S; Brugières L; Taque S; Guettier C; Fabre M; Rullier A; Buendia MA; Commes T; Grosset CF; Raymond AA
    Hepatology; 2018 Jul; 68(1):89-102. PubMed ID: 29152775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.
    Kerl K; Ries D; Unland R; Borchert C; Moreno N; Hasselblatt M; Jürgens H; Kool M; Görlich D; Eveslage M; Jung M; Meisterernst M; Frühwald M
    BMC Cancer; 2013 Jun; 13():286. PubMed ID: 23764045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of survivin in hepatoblastoma after chemotherapy.
    Uehara S; Oue T; Kawatsu M; Nara K; Fukuzawa M
    Eur J Pediatr Surg; 2013 Oct; 23(5):400-4. PubMed ID: 23444076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma.
    Espinoza AF; Patel RH; Patel KR; Badachhape AA; Whitlock R; Srivastava RK; Govindu SR; Duong A; Kona A; Kureti P; Armbruster B; Kats D; Srinivasan RR; Dobrolecki LE; Yu X; Najaf Panah MJ; Zorman B; Sarabia SF; Urbicain M; Major A; Bissig KD; Keller C; Lewis MT; Heczey A; Sumazin P; López-Terrada DH; Woodfield SE; Vasudevan SA
    J Hepatol; 2024 Apr; 80(4):610-621. PubMed ID: 38242326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
    Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IMPDH2 suppression impedes cell proliferation by instigating cell cycle arrest and stimulates apoptosis in pediatric hepatoblastoma.
    Li L; Wu Y; Huang HT; Yong JK; Lv Z; Zhou Y; Xiang X; Zhao J; Xi Z; Feng H; Xia Q
    J Cancer Res Clin Oncol; 2024 Aug; 150(8):377. PubMed ID: 39085725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
    Häberle B; Bode U; von Schweinitz D
    Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith-Wiedemann syndrome with high dose acetaminophen and N-acetylcysteine rescue.
    Kobrinsky NL; Sjolander DE; Goldenberg JA; Ortmeier TC
    Pediatr Blood Cancer; 2005 Aug; 45(2):222-5. PubMed ID: 15770640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential therapies for residual hepatoblastoma following incomplete ablation treatment in a nude mouse subcutaneous xenograft model based on lncRNA and mRNA expression profiles.
    Wang XD; Peng JB; Zhou CY; Que Q; Li HY; He Y; Yang H
    Oncol Rep; 2020 Jun; 43(6):1915-1927. PubMed ID: 32186781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nur77 inhibition of β-catenin expression mediates Hepatoblastoma progression and enhances cisplatin's therapeutic effect.
    Zhou J; Liu X; Yin H; Zhou Y; Xu Z; Zhou K; Li T; Fang Y; Shen Q
    Gene; 2024 May; 908():148292. PubMed ID: 38369247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma.
    Lieber J; Eicher C; Wenz J; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
    BMC Cancer; 2011 Aug; 11():362. PubMed ID: 21854558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma.
    Abril-Fornaguera J; Torrens L; Andreu-Oller C; Carrillo-Reixach J; Rialdi A; Balaseviciute U; Pinyol R; Montironi C; Haber PK; Del Río-Álvarez Á; Domingo-Sàbat M; Royo L; Akers NK; Willoughby CE; Peix J; Torres-Martin M; Puigvehi M; Cairo S; Childs M; Maibach R; Alaggio R; Czauderna P; Morland B; Losic B; Mazzaferro V; Guccione E; Sia D; Armengol C; Llovet JM
    Mol Cancer Ther; 2023 Apr; 22(4):485-498. PubMed ID: 36780225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology.
    von Schweinitz D; Byrd DJ; Hecker H; Weinel P; Bode U; Bürger D; Erttmann R; Harms D; Mildenberger H
    Eur J Cancer; 1997 Jul; 33(8):1243-9. PubMed ID: 9301450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatoblastoma presenting with lung metastases: treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors.
    Perilongo G; Brown J; Shafford E; Brock P; De Camargo B; Keeling JW; Vos A; Philips A; Pritchard J; Plaschkes J
    Cancer; 2000 Oct; 89(8):1845-53. PubMed ID: 11042582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma.
    Dewerth A; Wonner T; Lieber J; Ellerkamp V; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Pediatr Surg Int; 2012 Jun; 28(6):579-89. PubMed ID: 22526548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.